US2017114044A1PendingUtilityA1
Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders
Est. expiryFeb 5, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Takahiko TaniguchiAkira KawadaMitsuyo KondoJohn Frederick QuinnJun KunitomoMasato YoshikawaMakoto Fushimi
A61P 43/00A61P 3/10A61P 25/30A61P 25/22A61P 25/14A61P 3/00A61P 25/18A61P 3/04A61P 25/00A61P 25/32A61P 25/24A61P 25/28A61P 25/16C07D 413/04A61K 9/2059C07D 403/04C07D 413/14C07D 409/04C07D 401/14C07D 405/14C07D 405/04C07D 403/14C07D 409/14
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I 0 ) wherein R 1 represents a substituent, R 2 represents a hydrogen atom, or a substituent, R 3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of formula (I):
wherein
R 1 represents
a substituent,
R 2 represents
a hydrogen atom, or a substituent,
R 3 represents
a hydrogen atom, or a substituent,
Ring A represents
an aromatic ring which can be substituted, and
Ring B represents
a 5-membered heteroaromatic ring which can be substituted;
provided that the following compounds:
1-(2-chlorophenyl)-6-methyl-3-{5-thioxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1 H-1,2,4-triazol-3-yl}pyridazin-4(1H)-one,
1-(4-chlorophenyl)-3-[4-(2-fluorophenyl)-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-6-methylpyridazin-4(1H)-one,
1-(4-chlorophenyl)-6-methyl-3-{5-thioxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1H-1,2,4-triazol-3-yl}pyridazin-4(1H)-one,
1-(4-chlorophenyl)-3-[4-(2-fluorophenyl)-5-(methylsulfanyl)-4H-1,2,4-triazol-3-yl]-6-methylpyridazin-4(1H)-one,
1-(4-chlorophenyl)-6-methyl-3-{5-(methylsulfanyl)-4-[3-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}pyridazin-4(1H)-one,
1-(2-chlorophenyl)-6-methyl-3-{5-(methylsulfanyl)-4-[3-(trifluoromethyl)phenyl]-4H-1, 2,4-triazol-3-yl}pyridazin-4(1H)-one,
3-(3,5-dimethyl-1H-pyrazol-1-yl)-1-phenylpyridazin-4(1H)-one,
1-(4-chlorophenyl)-3-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-1H-pyrazol-5-yl}pyridazin-4(1H)-one,
3-[1-(2-fluorophenyl)-1H-pyrazol-5-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-[1-(3-chiorophenyl)-1H-pyrazol-5-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-[1-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-(1-phenyl-1H-pyrazol-5-yl)-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-[1-(3-nitrophenyl)-1H-pyrazol-5-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-[1-(1,1-dioxidotetrahydrothiophen-3-yl)-1H-pyrazol-5-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-[1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-phenylpyridazin-4(1H)-one,
3-[1-(4-chlorophenyl)-1H-pyrazol-5-yl]-1-phenylpyridazin-4(1H)-one,
3-(4-ethyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-1-(4-methylphenyl)pyridazin-4(1H)-one,
1-(4-chlorophenyl)-3-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-1H-pyrazol-3-yl}pyridazin-4(1H)-one,
3-[1-(2-fluorophenyl)-1H-pyrazol-3-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-[1-(3-methoxyphenyl)-1H-pyrazol-3-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-(1-phenyl-1H-pyrazol-3-yl)-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-[1-(3-nitrophenyl)-1H-pyrazol-3-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4(1H)-one,
3-[1-(4-methylphenyl)-1H-pyrazol-3-yl]-1-phenylpyridazin-4(1H)-one,
3-[1-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-phenylpyridazin-4(1H)-one,
a compound of formula:
wherein
Ring A′ is a benzene ring which can be substituted by one substituent selected from a halogen atom, and an alkyl group,
R 1′ is
(1) an ethyl group, or
(2) a phenyl group which can be substituted by one or more substituents selected from a fluorine atom, and a trifluoromethyl group,
R 3′ is a hydrogen atom, or a methyl group, and
Ra is a hydrogen atom, or a C 1-4 acyclic hydrocarbon group which can be substituted,
a compound of formula:
wherein
Ring A″ is a benzene ring which can be substituted by halogen, and
R 1″ is an acyl group
are excluded;
or a salt thereof.
2 . The compound according to claim 1 , wherein
R 2 represents a halogen atom, a hydroxy group, a C 1-10 alkyl group which can be substituted, or a C 1-10 alkoxy group which can be substituted.
3 . The compound according to claim 2 , wherein
R 2 represents a C 1-10 alkoxy group which can be substituted by one or more substituents selected from a halogen atom, a C 1-10 alkoxy group, and a C 3-7 cycloalkyl group.
4 . The compound according to claim 2 , wherein
R 2 represents a C 1-10 alkoxy group.
5 . The compound according to claim 2 , wherein
R 1 represents a phenyl group which can be substituted by 1 to 5 substituents selected from a halogen atom, a C 1-10 alkyl group which can be substituted, and a C 1-10 alkoxy group which can be substituted.
6 . The compound according to claim 2 , wherein
R 1 represents a phenyl group which can be substituted by 1 to 5 substituents selected from a halogen atom, a C 1-10 alkyl group, and a C 1-10 alkoxy group.
7 . The compound according to claim 2 , wherein
R 1 represents a phenyl group which can be substituted by 1 to 5 halogen atoms.
8 . The compound according to claim 2 , wherein
R 3 represents a hydrogen atom, or a C 1-10 alkoxy group which can be substituted.
9 . The compound according to claim 2 , wherein
R 3 represents a hydrogen atom, or a C 1-10 alkoxy group.
10 . The compound according to claim 2 , wherein
R 3 represents a hydrogen atom.
11 . The compound according to claim 2 , wherein
Ring A represents a benzene ring which can be substituted by 1 to 5 substituents selected from (1) a halogen atom, (2) a C 1-10 alkyl group which can be substituted, (3) a C 1-10 alkoxy group which can be substituted, (4) a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted, (5) a C 1-10 alkylsulfonyl group which can be substituted, (6) a C 3-7 cycloalkyl group which can be substituted, (7) a cyano group, (8) a carbamoyl group which can be substituted, (9) a C 1-10 alkylsulfonyloxy group which can be substituted, (10) a C 3-7 cycloalkyl-C 2-6 alkynyl group which can be substituted, (11) a tetrahydropyranyl group which can be substituted, (12) a dihydropyranyl group which can be substituted, (13) a mono-(C 1-10 alkyl-carbonyl)-amino group which can be substituted, (14) a C 1-10 alkoxy-carbonyl group which can be substituted, (15) a C 1-10 alkylsulfinyl group which can be substituted, and (16) a C 1-10 alkylsulfanyl group which can be substituted.
12 . The compound according to claim 2 , wherein
Ring A represents a benzene ring which can be substituted by 1 to 5 substituents selected from (1) a halogen atom, (2) a C 1-10 alkyl group which can be substituted, (3) a C 1-10 alkoxy group which can be substituted, (4) a C 3-7 cycloalkyl group, (5) a halogeno C 1-10 alkylsulfonyloxy group, (6) a C 3-7 cycloalkyl-C 2-6 alkynyl group, and (7) a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by one or more substituents selected from a halogen atom, a hydroxy group, an oxo group, a C 1-10 alkoxy-carbonyl group, a C 1-10 alkoxy group which can be substituted, and a C 1-10 alkyl group which can be substituted.
13 . The compound according to claim 2 , wherein
Ring A represents a benzene ring which can be substituted by 1 to 5 substituents selected from (1) a halogen atom, (2) a C 1-10 alkyl group which can be substituted by 1 to 3 halogen atoms, (3) a C 1-10 alkoxy group which can be substituted by 1 to 3 halogen atoms, (4) a C 3-7 cycloalkyl group, (5) a halogeno C 1-10 alkylsulfonyloxy group, (6) a C 3-7 cycloalkyl-C 2-6 alkynyl group, and (7) a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by 1 to 4 substituents selected from a halogen atom, a hydroxy group, an oxo group, a C 1-10 alkoxy-carbonyl group, a C 1-10 alkoxy group which can be substituted by halogen, and a C 1-10 alkyl group which can be substituted by halogen.
14 . The compound according to claim 2 , wherein
Ring A represents a benzene ring which is substituted with (1) (i) 1 or 2 halogen atoms, or (ii) one C 1-10 alkoxy group, and (2) one 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by 1 to 4 substituents selected from a halogen atom, a hydroxy group, an oxo group, a C 1-10 alkoxy-carbonyl group, a C 1-10 to alkoxy group which can be substituted by halogen, and a C 1-10 alkyl group which can be substituted by halogen.
15 . The compound according to claim 14 , wherein
the 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms represents a morpholino group, a pyrrolyl group, a dihydropyrrolyl group, a pyrazolyl group, a dihydropyrazolyl group, a piperidyl group, an azetidinyl group, a pyrrolidinyl group, an oxazolidinyl group, an imidazolyl group or an imidazolidinyl group.
16 . The compound according to claim 2 , wherein
Ring B represents an imidazole ring, a pyrazole ring, a triazole ring or a tetrazole ring, each of which can be further substituted with 1 to 3 substituents selected from a halogen atom, and a C 1-10 alkyl group which can be substituted by halogen.
17 . The compound according to claim 2 , wherein
Ring B represents a pyrazole ring which can be further substituted with 1 to 3 substituents selected from a halogen atom, and a C 1-10 alkyl group which can be substituted by halogen.
18 . The compound according to claim 2 , wherein
Ring B represents a pyrazole ring.
19 . The compound according to claim 2 , wherein
R 1 represents a phenyl group which can be substituted by 1 to 5 substituents selected from a halogen atom, a C 1-10 alkyl group which can be substituted, and a C 1-10 alkoxy group which can be substituted, R 2 represents a halogen atom, a hydroxy group, a C 1-10 alkyl group which can be substituted, or a C 1-10 alkoxy group which can be substituted, R 3 represents a hydrogen atom, or a C 1-10 alkoxy group which can be substituted, Ring A represents a benzene ring which can be substituted by 1 to 5 substituents selected from (1) a halogen atom, (2) a C 1-10 alkyl group which can be substituted, (3) a C 1-10 alkoxy group which can be substituted, (4) a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted, (5) a C 1-10 alkylsulfonyl group which can be substituted, (6) a C 3-7 cycloalkyl group which can be substituted, (7) a cyano group, (8) a carbamoyl group which can be substituted, (9) a C 1-10 alkylsulfonyloxy group which can be substituted, (10) a C 3-7 cycloalkyl-C 2-6 alkynyl group which can be substituted, (11) a tetrahydropyranyl group which can be substituted, (12) a dihydropyranyl group which can be substituted, (13) a mono-(C 1-10 alkyl-carbonyl)-amino group which can be substituted, (14) a C 1-10 alkoxy-carbonyl group which can be substituted, (15) a C 1-10 alkylsulfinyl group which can be substituted, and (16) a C 1-10 alkylsulfanyl group which can be substituted, and Ring B represents an imidazole ring, a pyrazole ring, a triazole ring or a tetrazole ring, each of which can be further substituted with 1 to 3 substituents selected from a halogen atom, and a C 1-10 alkyl group which can be substituted by halogen.
20 . The compound according to claim 19 , wherein.
Ring A represents a benzene ring which can be substituted by 1 to 5 substituents selected from (1) a halogen atom, (2) a C 1-10 alkyl group which can be substituted, (3) a C 1-10 alkoxy group which can be substituted, (4) a C 3-7 cycloalkyl group, (5) a halogeno C 1-10 alkylsulfonyloxy group, (6) a C 3-7 cycloalkyl-C 2-6 alkynyl group, and (7) a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by one or more substituents selected from a halogen atom, a hydroxy group, an oxo group, a C 1-10 alkoxy-carbonyl group, a C 1-10 alkoxy group which can be substituted, and a C 1-10 alkyl group which can be substituted.
21 . The compound according to claim 2 , wherein
R 1 represents a phenyl group which can be substituted by 1 to 5 substituents selected from a halogen atom, a C 1-10 alkyl group, and a C 1-10 alkoxy group, R 2 represents a C 1-10 alkoxy group which can be substituted by one or more substituents selected from a halogen atom, a C 1-10 alkoxy group, and a C 3-7 cycloalkyl group, R 3 represents a hydrogen atom, or a C 1-10 alkoxy group, Ring A represents a benzene ring which can be substituted by 1 to 5 substituents selected from (1) a halogen atom, (2) a C 1-10 alkyl group which can be substituted by 1 to 3 halogen atoms, (3) a C 1-10 alkoxy group which can be substituted by 1 to 3 halogen atoms, (4) a C 3-7 cycloalkyl group, (5) a halogeno C 1-10 alkylsulfonyloxy group, (6) a C 3-7 cycloalkyl-C 2-6 alkynyl group, and (7) a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by 1 to 4 substituents selected from a halogen atom, a hydroxy group, an oxo group, a C 1-10 alkoxy-carbonyl group, a C 1-10 alkoxy group which can be substituted by halogen, and a C 1-10 alkyl group which can be substituted by halogen, Ring B represents a pyrazole ring which can be further substituted with 1 to 3 substituents selected from a halogen atom, and a C 1-10 alkyl group which can be substituted by halogen.
22 . The compound according to claim 2 , wherein
R 1 represents a phenyl group which can be substituted by 1 to 5 halogen atoms, R 2 represents a C 1-10 alkoxy group, R 3 represents a hydrogen atom, Ring A represents a benzene ring which is substituted with (1) (i) 1 or 2 halogen atoms, or (ii) one C 1-10 alkoxy group, and (2) one 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by 1 to 4 substituents selected from a halogen atom, a hydroxy group, an oxo group, a C 1-10 alkoxy-carbonyl group, a C 1-10 alkoxy group which can be substituted by halogen, and a C 1-10 alkyl group which can be substituted by halogen, Ring B represents a pyrazole ring.
23 . The compound according to claim 22 , wherein
the 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms represents a morpholino group, a pyrrolyl group, a dihydropyrrolyl group, a pyrazolyl group, a dihydropyrazolyl group, a piperidyl group, an azetidinyl group, a pyrrolidinyl group, an oxazolidinyl group, an imidazolyl group or an imidazolidinyl group.
24 . The compound according to claim 1 , wherein
R 1 represents an aromatic group which can be substituted, Ring A represents an aromatic ring which is substituted with (a) one substituent selected from (1) a C 3-7 cycloalkyl group which can be substituted, and (2) a 4- to 6-membered heterocyclic group containing 1 to 5 heteroatoms selected from a nitrogen atom, a sulfur atom, and an oxygen atom which can be substituted, and (b) one or more further substituents.
25 . The compound according to claim 24 , wherein
R 1 represents a phenyl group which can be substituted, R 2 represents a hydrogen atom, a halogen atom, a hydroxy group, a C 1-10 alkyl group which can be substituted, or a C 1-10 alkoxy group which can be substituted, R 3 represents a hydrogen atom, or a C 1-10 alkoxy group which can be substituted, Ring A represents a benzene ring which is substituted with one substituent selected from (1) a C 3-7 cycloalkyl group which can be substituted, (2) a dihydropyranyl group which can be substituted, (3) a tetrahydropyranyl group which can be substituted, and (4) a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted, and can be substituted by further substituents, and Ring B represents an imidazole ring, a pyrazole ring, a triazole ring, a tetrazole ring, an isoxazole ring, an 1,3-oxazole ring, a furan ring, or a thiophene ring, each of which can be substituted.
26 . The compound according to claim 25 , wherein
the 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms represents a morpholino group, a pyrrolyl group, a dihydropyrrolyl group, a pyrazolyl group, a dihydropyrazolyl group, a piperidyl group, an azetidinyl group, a pyrrolidinyl group, an oxazolidinyl group, an imidazolyl group, an imidazolidinyl group, an isoxazolyl group, a pyridyl group, a piperazinyl group, or a thiazolyl group.
27 . The compound according to claim 24 , wherein
the further substituents are 1 to 4 substituents selected from (1) a halogen atom, (2) an oxo group, (3) a hydroxy group, (4) a C 1-10 alkyl group which can be substituted, (5) a C 1-10 alkoxy group which can be substituted, (6) a C 1-10 alkylsulfonyl group, (7) a morpholin-4-yl sulfonyl group, (8) a cyano group, (9) a carbamoyl group, (10) a halogeno C 1-10 alkylsulfonyloxy group, (11) a C 3-7 cycloalkyl-C 2-6 alkynyl group, (12) a di-C 1-10 alkyl-amino group, (13) a mono-(C 1-10 alkyl-carbonyl)-amino group, (14) a C 1-10 alkoxy-carbonyl group, (15) a phenoxy group, (16) a C 1-10 alkylsulfinyl group, (17) a di-C 1-10 alkyl-amino group, (18) a benzimidazole-2-yloxy group, and (19) a benzimidazole-2-yl sulfonyl group.
28 . The compound according to claim 24 , wherein
R 1 represents a phenyl group which can be substituted by 1 to 5 halogen atoms, R 2 represents a hydrogen atom or a C 1-10 alkoxy group, R 3 represents a hydrogen atom, Ring A represents a benzene ring, which is substituted with one 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by 1 to 4 substituents selected from a halogen atom, a hydroxy group, an oxo group, halogeno C 1-10 alkoxy group, a C 1-10 alkoxy-carbonyl, and a C 1-10 alkyl group which can be substituted by halogen, and which can be further substituted with 1 or 2 substituents selected from a halogen atom and a C 1-10 alkoxy group, and Ring B represents a pyrazole ring.
29 . The compound according to claim 28 , wherein
the 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms represents a morpholino group, a pyrrolyl group, a dihydropyrrolyl group, a pyrazolyl group, a dihydropyrazolyl group, a piperidyl group, an azetidinyl group, a pyrrolidinyl group, an oxazolidinyl group, an imidazolyl group or an imidazolidinyl group.
30 . 1-[2-fluoro-4-(3,3,4,4-tetrafluoropyrrolidin-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof.
31 . 1-[2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof.
32 . 1-[4-(3,4-difluoro-1H-pyrrol-1-yl)-2-fluorophenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof.
33 . 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof.
34 . 1-[4-(4-chloro-1H-pyrazol-1-yl)-2-fluorophenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof.
35 . 1-[2-fluoro-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof
36 . 3-[1-(2-fluorophenyl)-1H-pyrazol-5-yl]-1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxypyridazin-4(1H)-one, or a salt thereof.
37 . 3-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxypyridazin-4(1H)-one, or a salt thereof.
38 . 1-[4-(4,4-dimethyl-2-oxopyrrolidin-1-yl)-2-fluorophenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(I H)-one, or a salt thereof.
39 . 1-[4-(5,5-dimethyl-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof.
40 . 5-methoxy-1-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof.
41 . A prodrug of the compound according to claim 1
42 . A medicament comprising the compound according to claim 1 or a prodrug thereof.
43 . A medicament comprising a compound of formula (I 0 ):
wherein
R 1 represents
a substituent,
R 2 represents
a hydrogen atom, or a substituent,
R 3 represents
a hydrogen atom, or a substituent,
Ring A represents
an aromatic ring which can be substituted, and
Ring B represents
a 5-membered heteroaromatic ring which can be substituted,
or a salt thereof, or a prodrug thereof.
44 . The medicament according to claim 43 which is an agent for inhibiting phosphodiesterase 10A.
45 . The medicament according to claim 43 which is for preventing or treating schizophrenia
46 . A method of preventing or treating schizophrenia comprising administrating an effective amount of a compound of formula (I 0 ):
wherein
R 1 represents
a substituent,
R 2 represents
a hydrogen atom, or a substituent,
R 3 represents
a hydrogen atom, or a substituent,
Ring A represents
an aromatic ring which can be substituted, and
Ring B represents
a 5-membered heteroaromatic ring which can be substituted,
or a salt thereof, or a prodrug thereof
to a mammal.
47 . Use of a compound of formula (I 0 ):
wherein
R 1 represents
a substituent,
R 2 represents
a hydrogen atom, or a substituent,
R 3 represents
a hydrogen atom, or a substituent,
Ring A represents
an aromatic ring which can be substituted, and
Ring B represents
a 5-membered heteroaromatic ring which can be substituted,
or a salt thereof, or a prodrug thereof
as a medicament.
48 . Use of a compound of formula (I 0 ):
wherein
R 1 represents
a substituent,
R 2 represents
a hydrogen atom, or a substituent,
R 3 represents
a hydrogen atom, or a substituent,
Ring A represents
an aromatic ring which can be substituted, and
Ring B represents
a 5-membered heteroaromatic ring which can be substituted,
or a salt thereof, or a prodrug thereof
in the manufacture of a medicament for preventing or treating schizophrenia.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.